Companies › Zogenix
1 active drug program in 4 registered trials: 2 Phase 4, 1 Phase 3, 1 Phase 2; Neurology; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Fenfluramine Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist | HTR1D, HTR2C, SIGMAR1 | Phase 3 | CDKL5 Deficiency Disorder; Dravet Syndrome (DS); Dravet Syndrome; Infantile Spasm | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06598449 | Fenfluramine | Phase 4 | Dravet Syndrome (DS) | Neurology | Dec 2026 |
| NCT04289467 | Fenfluramine | Phase 2 | Infantile Spasm | Neurology | Dec 2026 |
| NCT07112365 | Fenfluramine | Phase 4 | Dravet Syndrome | Neurology | Sep 2027 |
| NCT05064878 | Fenfluramine | Phase 3 | CDKL5 Deficiency Disorder | Neurology | Nov 2027 |
UCB BIOSCIENCES Exciva Technophage Boryung Pharmaceutical Tonix Pharmaceuticals Anavex Life Sciences Pentixapharm CSPC Ouyi Pharmaceutical
Bigespas JYAMS PET Research & Development Longboard Pharmaceuticals TriGemX Bio ML Bio Solutions
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.